John Byrd, MD, Hematology, Columbus, OH, Ohio State University Wexner Medical Center

JohnC.ByrdMD

Hematology Columbus, OH

D. Warren Brown Chair of Leukemia Research; Distinguished University Professor of Medicine, Medicinal Chemistry, and Veterinary Biosciences; Division of Hematology, Department of Medicine; The Ohio State University

Dr. Byrd is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Byrd's full profile

Already have an account?

Summary

  • I am a physician scientist who has done translational and clinical drug development for two decades. My laboratory and clinical work has directly resulted in 4 drugs getting FDA approval. This experience bridges close interaction with industry as a consultant to develop and implement a successful development plan (Calistoga, Idelalisib) to performing pre-clinical and clinical work in my University role focused on a single class of drugs that transformed the care of CLL (Ibrutinib, Acalabrutinib) and other B-cell malignancies. My role in the current Leukemia and Lymphoma Society Beat AML Study as Principal and Chief Medical Officer has offered an even larger extension of this by planning, implementing, and running a multi-center umbrella study in AML that brings together academic clinical investigators, diagnostic companies, pharmaceutical companies, clinical research organizations and the FDA to effectively move new drugs forward for potential registration in AML.

Education & Training

  • Walter Reed Army Medical CenterFELLOWSHIP
  • Walter Reed Army Medical Center
    Walter Reed Army Medical CenterRESIDENCY
  • University of Arkansas for Medical Sciences College of Medicine
    University of Arkansas for Medical Sciences College of MedicineMEDICAL_SCHOOL
  • Hendrix CollegeOTHER_TRAINING

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2001 - 2021
  • VA State Medical License
    VA State Medical License 1993 - 2020
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Return of the Child Award Leukemia and Lymphoma Society, 2017
  • Fellow American College of Physicians, 2017
  • Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research AACR, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • HSP90 Inhibition Without Heat Shock Response  
    John Byrd, MD, Blood
  • Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma  
    Rosko A, Hofmeister C, Benson D, Efebera Y, Huang Y, Gillahan J, Byrd JC, Burd CE, Bone Marrow Transplant, 1/1/2015
  • Emerging Drug Profile: Cyclin-Dependent Kinase Inhibitors  
    Blachly JS, Byrd JC, Leuk Lymphoma, 1/1/2013
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
    John C Byrd, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
    John C Byrd, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leuke...
    John C Byrd, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • What Patients with CLL/SLL Should Know About the FDA
    What Patients with CLL/SLL Should Know About the FDANovember 27, 2019
  • Ohio State-Developed Drug Receives FDA Approval for Treatment of CLL and SML
    Ohio State-Developed Drug Receives FDA Approval for Treatment of CLL and SMLNovember 22, 2019
  • Ohio State Earns FDA Approval for Leukemia Treatment
    Ohio State Earns FDA Approval for Leukemia TreatmentNovember 22, 2019
  • Join now to see all

Grant Support

  • Lenalidomide As An Immune Modulating Agent For Chronic Lymphocytic LeukemiaNational Cancer Institute2009–2011
  • Experimental Therapeutics Of LeukemiaNational Cancer Institute2009–2011
  • Administration And OperationsNational Cancer Institute2009–2011
  • Translational Training Grant In Experimental TherapeuticsNational Cancer Institute2008–2011
  • Innate Immune Therapies In B Cell MalignanciesNational Cancer Institute2007–2011
  • 2010 Clinical Research Training Institute Summer WorkshopNational Heart, Lung, And Blood Institute2010
  • Clinical Investigation Of Epigenetic TherapyNational Cancer Institute2006–2010
  • Clinical Trial OfficeNational Cancer Institute2005–2009
  • Hu1d10 In CLL: Clinical And Laboratory StudiesNational Cancer Institute2003–2006
  • Molecular Markers: Response To Chemo-Immunotherapy In C*National Cancer Institute2005
  • Epigenetic Targeted Therapy For Chronic Lymphocytic Leu*National Cancer Institute2005
  • Molecular Markers: Response To Chemo-Immunotherapy In CLNational Cancer Institute2004
  • Chronic Lymphocytic Leukemia:Epigenetic Targeted TherapyNational Cancer Institute2004
  • Depsipeptide: A Novel Histone Deacytlase Inhibitor In LNational Cancer Institute2002–2003
  • Clinical Investigation Of The Innate Immune SystemNational Cancer Institute2002
  • A Phase 1 Study Of Hud10 In Cll/Sll PatientsNational Cancer Institute2001–2002
  • Cancer And Leukemia Group BNational Cancer Institute1999

Professional Memberships

Hospital Affiliations